Applied BioCode Raises $13.2M in Public Stock Offering

Oct 30, 2018

NEW YORK (GenomeWeb) – Applied BioCode announced today that it has secured $13.2 million through a public offering of its common stock.

In addition, the firm said it has also secured $8 million in total credit lines extended from an undisclosed FDIC-insured financial institution and a commercial lender.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Applied BioCode Raises $13.2M in Public Stock Offering

To read the full story....

Breaking News

Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

FDA Grants First ASCA Accreditations to Labs to Perform Premarket Testing

Top Five Articles on 360Dx Last Week: NIH RADx, LumiraDx, Abbott, And More

Amazon to Give Out $12M Under Next Phase of AWS Diagnostics Development Initiative

Lucira Health Nabs OTC EUA for SARS-CoV-2 Test, Expects Q1 Revenues of up to $4.5M

DiaSorin to Acquire Luminex for $1.8B

Featured White Papers

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

DiaSorin to Acquire Luminex for $1.8B

CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

Sponsorships